Neorich Biopharma Tech Co Limited Statistics
Want to see NRBP full AI Analyst Report?
Neorich Biopharma Tech Co Limited (NRBP) Stock Statistics & Valuation Metrics
Total Valuation
Neorich Biopharma Tech Co Limited has a market cap or net worth of $293.82K. The enterprise value is $722.72B.
- Market Cap
- $293.82K
- Enterprise Value
- $722.72B
Share Statistics
Neorich Biopharma Tech Co Limited has 345,673 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 345,673
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Neorich Biopharma Tech Co Limited’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is 12.51%.
- Return on Equity (ROE)
- -0.15
- Return on Assets (ROA)
- 53.87
- Return on Invested Capital (ROIC)
- 12.51%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- 0.32
- Inventory Turnover
- 0.46
Valuation Ratios
The current PE Ratio of Neorich Biopharma Tech Co Limited is -0.20. Neorich Biopharma Tech Co Limited’s PEG ratio is 0.00.
- PE Ratio
- -0.20
- PS Ratio
- 0.07
- PB Ratio
- -0.03
- Price to FCF
- -18.94
- Price to Operating Cash Flow
- -18.18
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Neorich Biopharma Tech Co Limited had revenue of 2,388 and earned 406.36K in profits. Earnings per share was 0.60.
- Revenue
- 2,388
- Gross Profit
- -400
- Operating Income
- -290.49K
- Pretax Income
- 406.36K
- Net Income
- 406.36K
- EBITDA
- -290.49K
- Earnings Per Share (EPS)
- 0.60
Cash Flow
In the last 12 months, operating cash flow was -23.30K and capital expenditures -3, giving a free cash flow of -23.31K billion.
- Operating Cash Flow
- -23.30K
- Free Cash Flow
- -23.31K
- Free Cash Flow per Share
- -0.05
Dividends & Yields
Neorich Biopharma Tech Co Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.28%
- Earnings Yield
- -421.78%
Stock Price Statistics
- Beta
- 0.70
- 52-Week Price Change
- -95.60%
- 50-Day Moving Average
- 0.50
- 200-Day Moving Average
- 0.51
- Relative Strength Index (RSI)
- 66.32
- Average Volume (3m)
- 1,492
Important Dates
Neorich Biopharma Tech Co Limited upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Dec 19, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Neorich Biopharma Tech Co Limited as a current ratio of 0.00, with Debt / Equity ratio of -13.51%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.54
- Net Debt to EBITDA
- -1.22
- Interest Coverage Ratio
- -6.93
Taxes
In the past 12 months, Neorich Biopharma Tech Co Limited has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Neorich Biopharma Tech Co Limited EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -20.84.
- EV to Sales
- 0.08
- EV to EBITDA
- -0.27
- EV to Free Cash Flow
- -20.84
- EV to Operating Cash Flow
- -20.85
Balance Sheet
Neorich Biopharma Tech Co Limited has $721.00 in cash and marketable securities with $355.59K in debt, giving a net cash position of -$354.87K billion.
- Cash & Marketable Securities
- $721.00
- Total Debt
- $355.59K
- Net Cash
- -$354.87K
- Net Cash Per Share
- -$1.03
- Tangible Book Value Per Share
- -$8.07
Margins
Gross margin is -0.02%, with operating margin of -31.60%, and net profit margin of -29.06%.
- Gross Margin
- -0.02%
- Operating Margin
- -31.60%
- Pretax Margin
- -29.06%
- Net Profit Margin
- -29.06%
- EBITDA Margin
- -29.30%
- EBIT Margin
- -29.30%
Analyst Forecast
The average price target for Neorich Biopharma Tech Co Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 167846.30%
- EPS Growth Forecast
- -295.83%
Scores
- Smart Score
- ―
- AI Score
- 46
